Krystal Biotech (KRYS) Competitors

$314.86 +2.28 (+0.73%)

As of 03:09 PM Eastern

KRYS vs. RVMD, INSM, BNTX, ROIV, and MRNA

Should you buy Krystal Biotech stock or one of its competitors? MarketBeat compares Krystal Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Krystal Biotech include Revolution Medicines (RVMD), Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Krystal Biotech compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Revolution Medicines had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 15 mentions for Revolution Medicines and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.72 beat Revolution Medicines' score of 0.28 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines currently has a consensus target price of $103.88, indicating a potential downside of 30.35%. Krystal Biotech has a consensus target price of $324.11, indicating a potential upside of 2.94%. Given Krystal Biotech's higher possible upside, analysts clearly believe Krystal Biotech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	3.10
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Revolution Medicines has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Revolution Medicines' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Krystal Biotech	$417.30M	22.24	$204.83M	$7.48	42.09

Summary

Krystal Biotech beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Insmed?

Insmed (NASDAQ:INSM) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Krystal Biotech has a net margin of 53.92% compared to Insmed's net margin of -144.44%. Krystal Biotech's return on equity of 19.25% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	41.57	-$1.28B	-$5.75	N/A
Krystal Biotech	$417.30M	22.24	$204.83M	$7.48	42.09

Insmed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

In the previous week, Insmed had 26 more articles in the media than Krystal Biotech. MarketBeat recorded 37 mentions for Insmed and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.72 beat Insmed's score of 0.56 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	14 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Insmed currently has a consensus target price of $210.95, indicating a potential upside of 81.40%. Krystal Biotech has a consensus target price of $324.11, indicating a potential upside of 2.94%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Krystal Biotech has a net margin of 53.92% compared to BioNTech's net margin of -44.39%. Krystal Biotech's return on equity of 19.25% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.16	-$1.29B	-$5.88	N/A
Krystal Biotech	$417.30M	22.24	$204.83M	$7.48	42.09

BioNTech has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

In the previous week, BioNTech had 2 more articles in the media than Krystal Biotech. MarketBeat recorded 13 mentions for BioNTech and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.72 beat BioNTech's score of 0.58 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioNTech currently has a consensus target price of $130.60, indicating a potential upside of 42.10%. Krystal Biotech has a consensus target price of $324.11, indicating a potential upside of 2.94%. Given BioNTech's higher possible upside, equities research analysts clearly believe BioNTech is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Krystal Biotech (NASDAQ:KRYS) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Roivant Sciences' net margin of -6,079.94%. Krystal Biotech's return on equity of 19.25% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Krystal Biotech presently has a consensus target price of $324.11, indicating a potential upside of 2.94%. Roivant Sciences has a consensus target price of $30.55, indicating a potential upside of 3.72%. Given Roivant Sciences' higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$417.30M	22.24	$204.83M	$7.48	42.09
Roivant Sciences	$29.05M	725.68	-$171.98M	-$1.17	N/A

Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

In the previous week, Krystal Biotech had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Krystal Biotech and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.76 beat Krystal Biotech's score of 0.72 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Roivant Sciences on 11 of the 15 factors compared between the two stocks.

How does Krystal Biotech compare to Moderna?

Krystal Biotech (NASDAQ:KRYS) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Krystal Biotech has a net margin of 53.92% compared to Moderna's net margin of -143.55%. Krystal Biotech's return on equity of 19.25% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Moderna	-143.55%	-26.64%	-19.32%

Krystal Biotech presently has a consensus target price of $324.11, indicating a potential upside of 2.94%. Moderna has a consensus target price of $35.73, indicating a potential downside of 28.69%. Given Krystal Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Krystal Biotech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Moderna had 22 more articles in the media than Krystal Biotech. MarketBeat recorded 33 mentions for Moderna and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.72 beat Moderna's score of 0.65 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	19 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Krystal Biotech has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$417.30M	22.24	$204.83M	$7.48	42.09
Moderna	$2.20B	9.02	-$2.82B	-$8.15	N/A

Summary

Krystal Biotech beats Moderna on 13 of the 16 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.31B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	42.20	18.77	20.85	25.56
Price / Sales	22.24	263.59	543.57	72.25
Price / Cash	42.57	122.51	42.94	55.34
Price / Book	7.27	6.77	9.87	6.72
Net Income	$204.83M	$24.11M	$3.55B	$333.62M
7 Day Performance	6.12%	0.17%	-0.23%	0.35%
1 Month Performance	16.61%	0.98%	1.47%	4.00%
1 Year Performance	139.64%	78.11%	41.05%	36.32%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	2.8993 of 5 stars	$314.86 +0.7%	$324.11 +2.9%	+132.3%	$9.31B	$417.30M	42.20	210
RVMD Revolution Medicines	2.2526 of 5 stars	$147.90 +6.0%	$78.94 -46.6%	+275.3%	$29.65B	$11.58M	N/A	250	Analyst Revision
INSM Insmed	3.1636 of 5 stars	$140.01 +5.1%	$213.23 +52.3%	+79.6%	$28.76B	$606.42M	N/A	1,664	Earnings Report Analyst Forecast Analyst Revision
BNTX BioNTech	3.8392 of 5 stars	$99.35 +1.9%	$133.13 +34.0%	-2.4%	$24.67B	$3.25B	N/A	7,807	Analyst Forecast Buyback Announcement
ROIV Roivant Sciences	2.3431 of 5 stars	$28.36 +1.9%	$30.55 +7.7%	+171.6%	$19.92B	$29.05M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. RVMD, INSM, BNTX, ROIV, and MRNA

How does Krystal Biotech compare to Revolution Medicines?

Summary

How does Krystal Biotech compare to Insmed?

Summary

How does Krystal Biotech compare to BioNTech?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Summary

How does Krystal Biotech compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. RVMD, INSM, BNTX, ROIV, and MRNA

How does Krystal Biotech compare to Revolution Medicines?

Do institutionals & insiders believe in RVMD or KRYS?

Does the media prefer RVMD or KRYS?

Do analysts recommend RVMD or KRYS?

Which has more volatility & risk, RVMD or KRYS?

Is RVMD or KRYS more profitable?

Which has better earnings & valuation, RVMD or KRYS?

Summary

How does Krystal Biotech compare to Insmed?

Is INSM or KRYS more profitable?

Which has better earnings & valuation, INSM or KRYS?

Which has more volatility & risk, INSM or KRYS?

Does the media prefer INSM or KRYS?

Do institutionals & insiders believe in INSM or KRYS?

Do analysts recommend INSM or KRYS?

Summary

How does Krystal Biotech compare to BioNTech?

Is BNTX or KRYS more profitable?

Which has preferable valuation and earnings, BNTX or KRYS?

Which has more volatility and risk, BNTX or KRYS?

Does the media favor BNTX or KRYS?

Do insiders and institutionals believe in BNTX or KRYS?

Do analysts prefer BNTX or KRYS?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Do institutionals and insiders believe in KRYS or ROIV?

Is KRYS or ROIV more profitable?

Do analysts prefer KRYS or ROIV?

Which has better valuation & earnings, KRYS or ROIV?

Which has more risk and volatility, KRYS or ROIV?

Does the media favor KRYS or ROIV?

Summary

How does Krystal Biotech compare to Moderna?

Is KRYS or MRNA more profitable?

Do analysts prefer KRYS or MRNA?

Do institutionals and insiders believe in KRYS or MRNA?

Does the media favor KRYS or MRNA?

Which has more risk and volatility, KRYS or MRNA?

Which has better valuation & earnings, KRYS or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools